FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Berger

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Devices

Stents

Co-author Network

Publications

TOP 3
Adnan Kastrati; Karl-Ludwig Laugwitz; Steffen Massberg; Julinda Mehilli; Franz-Josef Neumann; Ilka Ott; Jürgen Pache; Albert Schömig; Stefanie Schulz; Melchior Seyfarth; David Antoniucci; Peter B Berger; Robert A Byrne; Miroslaw Ferenc; Michael Gick; Jörg Hausleiter
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz-Josef Neumann; Katrin A Birkmeier; Sebastian Kufner; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.
Gjin Ndrepepa; Stefanie Schulz; Dritan Keta; Julinda Mehilli; Anette Birkmeier; Steffen Massberg; Karl-Ludwig Laugwitz; Franz-Josef Neumann; Melchior Seyfarth; Peter B Berger; Albert Schömig; Adnan Kastrati
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Berger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Adnan Kastrati; Karl-Ludwig Laugwitz; Steffen Massberg; Julinda Mehilli; Franz-Josef Neumann; Ilka Ott; Jürgen Pache; Albert Schömig; Stefanie Schulz; Melchior Seyfarth; David Antoniucci; Peter B Berger; Robert A Byrne; Miroslaw Ferenc; Michael Gick; Jörg Hausleiter
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
The New England journal of medicine 2011;365(21):1980-9.
2010: Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz-Josef Neumann; Katrin A Birkmeier; Sebastian Kufner; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.
European heart journal 2010;31(5):582-7.
2010: Gjin Ndrepepa; Stefanie Schulz; Dritan Keta; Julinda Mehilli; Anette Birkmeier; Steffen Massberg; Karl-Ludwig Laugwitz; Franz-Josef Neumann; Melchior Seyfarth; Peter B Berger; Albert Schömig; Adnan Kastrati
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
The American journal of cardiology 2010;105(2):163-7.
2009: Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Robert A Byrne; Stefanie Schulz; Franz-Josef Neumann; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
European heart journal 2009;30(3):290-6.
2008: Adnan Kastrati; Franz-Josef Neumann; Julinda Mehilli; Robert A Byrne; Raisuke Iijima; Heinz Joachim Büttner; Ahmed A Khattab; Stefanie Schulz; James C Blankenship; Jürgen Pache; Jan Minners; Melchior Seyfarth; Isolde Graf; Kimberly A Skelding; Josef Dirschinger; Gert Richardt; Peter B Berger; Albert Schömig
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
The New England journal of medicine 2008;359(7):688-96.
2008: Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Franz-Josef Neumann; Stefanie Schulz; Jurriën ten Berg; Olga Bruskina; Franz Dotzer; Josef Dirschinger; Peter B Berger; Albert Schömig; Adnan Kastrati
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Clinical research in cardiology : official journal of the German Cardiac Society 2008;97(3):160-8.
2008: Gjin Ndrepepa; Peter B Berger; Julinda Mehilli; Melchior Seyfarth; Franz-Josef Neumann; Albert Schömig; Adnan Kastrati
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
Journal of the American College of Cardiology 2008;51(7):690-7.
2008: Gjin Ndrepepa; Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Jurriën M ten Berg; Olga Bruskina; Franz Dotzer; Melchior Seyfarth; Jürgen Pache; Josef Dirschinger; Peter B Berger; Albert Schömig
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
European heart journal 2008;29(4):455-61.
2007: Julinda Mehilli; Gjin Ndrepepa; Adnan Kastrati; Franz-Josef Neumann; Jurriën M ten Berg; Olga Bruskina; Franz Dotzer; Melchior Seyfarth; Jürgen Pache; Sebastian Kufner; Josef Dirschinger; Peter B Berger; Albert Schömig
Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
American heart journal 2007;154(1):158.e1-7.
2006: Gjin Ndrepepa; Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Jurriën M ten Berg; Olga Bruskina; Franz Dotzer; Melchior Seyfarth; Jürgen Pache; Josef Dirschinger; Kurt Ulm; Peter B Berger; Albert Schömig
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
Circulation 2006;114(19):2040-6.
2006: Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën M ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
JAMA : the journal of the American Medical Association 2006;295(13):1531-8.
2006: Carey D Moyer; Peter B Berger
Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction.
Evidence-based medicine 2006;11(1):14.
2006: Carey D Moyer; Peter B Berger
Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction.
ACP journal club 2006;144(1):15.
2005: Donal N Reddan; Lynda Szczech; Manjushri Bhapkar; David J Moliterno; Robert M Califf; Erik Ohman; Peter B Berger; Judith S Hochman; Frans Van de Werf; Robert A Harrington; L Kristin Newby
Renal function, concomitant medication use and outcomes following acute coronary syndromes.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(10):2105-12.
2005: Peter B Berger
A glucose-insulin-potassium infusion did not reduce mortality, cardiac arrest, or cardiogenic shock after acute MI.
ACP journal club 2005;143(1):4-5.
2005: Peter B Berger
Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI.
ACP journal club 2005;143(1):4-5.
2005: Albert Schömig; Claus Schmitt; Alban Dibra; Julinda Mehilli; Christian Volmer; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Peter B Berger; Adnan Kastrati
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
European heart journal 2005;26(14):1379-84.
2004: David E Kandzari; Peter B Berger; Adnan Kastrati; Steven R Steinhubl; Julinda Mehilli; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Hildegard Bollwein; Josef Dirschinger; Albert Schömig
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
Journal of the American College of Cardiology 2004;44(11):2133-6.
2004: Peter B Berger
Percutaneous transluminal coronary angioplasty improved long-term angina status more than medical therapy in coronary artery disease.
ACP journal club 2004;141(2):34.
2004: David E Kandzari; Alan Chu; Bruce R Brodie; Thomas A Stuckey; James Hermiller; George W Vetrovec; Karen L Hannan; Mitchell W Krucoff; Robert H Christenson; Raymond J Gibbons; Kristina N Sigmon; Jyotsna Garg; Vic Hasselblad; Kenneth Collins; Robert A Harrington; Peter B Berger; Nicholas A Chronos; Judith S Hochman; Robert M Califf
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study).
The American journal of cardiology 2004;93(5):636-9.
2004: Adnan Kastrati; Julinda Mehilli; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Hildegard Bollwein; Christian Volmer; Meinrad Gawaz; Peter B Berger; Albert Schömig
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
The New England journal of medicine 2004;350(3):232-8.
2003: Thaddeus R Tolleson; L Kristin Newby; Robert A Harrington; Manjushri Bhapkar; Freek W A Verheugt; Peter B Berger; David J Moliterno; Harvey D White; Erik Ohman; Frans Van de Werf; Eric J Topol; Robert M Califf
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
The American journal of cardiology 2003;92(3):330-3.